This study, called NOTRE, is looking at the best ways to provide HIV prevention (Pre-Exposure Prophylaxis or PrEP) and treatment for Opioid Use Disorder (OUD) to people who are in jail or prison and will be released soon. Researchers are comparing different forms of these medications: long-acting injectable Cabotegravir (for PrEP) and Buprenorphine (for OUD) versus oral Cabotegravir and Buprenorphine pills. The goal is to see which approach works best for people in these settings. You might be able to join if you are an adult (18 or older) in a participating jail or prison, are expected to be released within 120 days, and have a history of OUD. The study will measure how well people stick to their PrEP and Buprenorphine treatments for up to 12 months. The current recruitment status is unclear.

Study design

This study is a hybrid type 2 implementation-effectiveness trial that includes a randomized control trial with 450 participants.

What's involved

Participants will have a baseline assessment before release, followed by monthly follow-up for 7 months, and a final visit at 12 months.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 12 months after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.